Marker Therapeutics, Inc. (MRKR)

NASDAQ: MRKR · IEX Real-Time Price · USD
0.365
-0.034 (-8.61%)
Aug 16, 2022 11:17 AM EDT - Market open
-8.61%
Market Cap 30.51M
Revenue (ttm) 3.00M
Net Income (ttm) -41.35M
Shares Out 83.60M
EPS (ttm) -0.52
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 342,442
Open 0.390
Previous Close 0.399
Day's Range 0.363 - 0.400
52-Week Range 0.250 - 2.050
Beta 1.27
Analysts Buy
Price Target 2.93 (+702.7%)
Earnings Date Aug 8, 2022

About MRKR

Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications in the United States. Its MultiTAA-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens and kill tumor cells expressing tumor-associated antigens. The company's MultiTAA-specific T cell therapies ... [Read more...]

Industry Biotechnology
CEO Peter Hoang
Employees 56
Stock Exchange NASDAQ
Ticker Symbol MRKR
Full Company Profile

Financial Performance

In 2021, MRKR's revenue was $1.24 million, an increase of 166.01% compared to the previous year's $466,785. Losses were -$41.88 million, 45.9% more than in 2020.

Financial Statements

Analyst Forecast

According to 10 analysts, the average rating for MRKR stock is "Buy." The 12-month stock price forecast is 2.93, which is an increase of 702.74% from the latest price.

Price Target
$2.93
(702.74% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Marker Therapeutics Reports Q2 2022 Operating and Financial Results

HOUSTON, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherap...

Marker Therapeutics Announces FDA Clearance of IND for MT-601, the six-antigen targeted T Cell Therapy for the treatm...

Company expects to initiate Phase 1 trial of MT-601 in r/r NHL in 2023 Company expects to initiate Phase 1 trial of MT-601 in r/r NHL in 2023

Marker Therapeutics Reports Q1 2022 Operating and Financial Results

Topline readout of Phase 2 AML trial Group 2 active disease anticipated in Q2 2022

Marker Therapeutics to Present Four Posters on its T Cell-Based Immunotherapies at the 2022 International Society for...

HOUSTON, May 04, 2022 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapi...

Marker Therapeutics Reports Fiscal Year 2021 Operating and Financial Results

Enrollment of first 20 patients of the Company's Phase 2 acute myeloid leukemia (AML) trial completed in Q4 2021

Marker Therapeutics to Present at Two Upcoming March Investor Conferences

HOUSTON, March 07, 2022 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc.  (NASDAQ:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunothera...

Why Are Marker Therapeutics Shares Trading Lower On Thursday?

Marker Therapeutics Inc (NASDAQ: MRKR) shares are trading lower after Roth Capital downgrades the company from Buy to Neutral and lowers the price target from $3 to $1. The company reported initial resu...

Marker Therapeutics Announces Clinical Program Updates and Pipeline Expansion

Results from safety lead-in stage of Marker's Phase 2 AML trial demonstrate that MT-401 was well-tolerated, eliminated measurable residual disease (MRD) in one MRD+ patient and induced epitope spreading

Marker Therapeutics to Host Clinical Program Update Conference Call and Webcast on Wednesday, February 16, 2022

HOUSTON, Feb. 08, 2022 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapi...

Marker Therapeutics Stock Gains On FDA Orphan Drug Tag For Second MultiTAA-Cell Therapy For Pancreatic Cancer

The FDA has granted Orphan Drug Designation to Marker Therapeutics Inc's (NASDAQ: MRKR) MT-601, a multi-tumor-associated antigen (MultiTAA)-specific T cell product for pancreatic cancer. Following MT-40...

Marker Therapeutics Receives FDA Orphan Drug Designation for its Multi-Antigen Targeted T Cell Therapy for Pancreatic...

HOUSTON, Jan. 19, 2022 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc.  (NASDAQ:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherap...

Marker Therapeutics Appoints Biotech Executive Katharine Knobil, M.D., to Board of Directors

HOUSTON, Dec. 9, 2021 /PRNewswire/ -- Marker Therapeutics, Inc.  (NASDAQ: MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies ...

Marker Therapeutics Announces that Data from Investigator-Sponsored Phase 1 Study With its MultiTAA-Specific T Cells ...

HOUSTON, Nov. 18, 2021 /PRNewswire/ --  Marker Therapeutics, Inc.  (NASDAQ: MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapie...

Marker Therapeutics Reports Third Quarter 2021 Operating and Financial Results

HOUSTON, Nov. 10, 2021 /PRNewswire/ -- Marker Therapeutics, Inc. (Nasdaq:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies f...

Marker Therapeutics to Present at Three Upcoming September Investor Conferences

HOUSTON, Sept. 7, 2021 /PRNewswire/ --  Marker Therapeutics, Inc.  (NASDAQ:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies...

Marker Therapeutics Secures $13.1M Grant To Support MultiTAA Cell Therapy Trial

Marker Therapeutics Inc (NASDAQ: MRKR) received notice of a Product Development Research award of approximately $13.1 million from Texas's Cancer Prevention and Research Institute (CPRIT). The CPRIT awa...

Marker Therapeutics Awarded $13.1 Million Grant from the Cancer Prevention and Research Institute of Texas

HOUSTON, Aug. 19, 2021 /PRNewswire/ -- Marker Therapeutics, Inc. (Nasdaq:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies f...

Marker Therapeutics Reports Second Quarter 2021 Operating and Financial Results

HOUSTON, Aug. 10, 2021 /PRNewswire/ -- Marker Therapeutics, Inc. (Nasdaq:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies f...

Marker Therapeutics Announces Opening of New cGMP Manufacturing Facility

HOUSTON, July 28, 2021 /PRNewswire/ -- Marker Therapeutics, Inc. (Nasdaq:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies f...

Marker Therapeutics Announces Completion of Safety Lead-In Portion of Phase 2 Study in Post-Transplant AML

HOUSTON, July 6, 2021 /PRNewswire/ -- Marker Therapeutics, Inc. (Nasdaq:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies fo...

Marker Therapeutics to Present at the Virtual Raymond James Human Health Innovation Conference

HOUSTON, June 16, 2021 /PRNewswire/ -- Marker Therapeutics, Inc. (NASDAQ:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies f...

Marker Therapeutics Reports First Quarter 2021 Operating and Financial Results

HOUSTON, May 12, 2021 /PRNewswire/ -- Marker Therapeutics, Inc. (Nasdaq:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies fo...

Marker Therapeutics to Host First Quarter 2021 Operating and Financial Results Conference Call and Webcast on Wednesd...

HOUSTON, April 29, 2021 /PRNewswire/ -- Marker Therapeutics, Inc. (Nasdaq:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies ...

Marker Therapeutics to Present Multi-Tumor-Associated Antigen (mTAA)-Specific T Cell Manufacturing Robotics Data at t...

HOUSTON, April 27, 2021 /PRNewswire/ -- Marker Therapeutics, Inc. (Nasdaq:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies ...

Do Options Traders Know Something About Marker Therapeutics (MRKR) Stock We Don't?

Investors need to pay close attention to Marker Therapeutics (MRKR) stock based on the movements in the options market lately.